Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback